Volume 132, Issue 1, Pages 103-112 (January 2007) Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C  Mitchell L. Shiffman, Marc G. Ghany, Timothy R. Morgan, Elizabeth C. Wright, Gregory T. Everson, Karen L. Lindsay, Anna S.F. Lok, Herbert L. Bonkovsky, Adrian M. Di Bisceglie, William M. Lee, Jules L. Dienstag, David R. Gretch  Gastroenterology  Volume 132, Issue 1, Pages 103-112 (January 2007) DOI: 10.1053/j.gastro.2006.11.011 Copyright © 2007 AGA Institute Terms and Conditions

Figure 1 Relapse rates following retreatment with peginterferon and ribavirin in patients with chronic hepatitis C, advanced fibrosis or cirrhosis, and prior nonresponse. Relapse rate is plotted as a function of the percentage maximal ribavirin dose received during the first 20 weeks of treatment. Gastroenterology 2007 132, 103-112DOI: (10.1053/j.gastro.2006.11.011) Copyright © 2007 AGA Institute Terms and Conditions

Figure 2 Relationship between ribavirin dose expressed in mg/kg and W20 VR (A) and SVR (B) at 2 doses of peginterferon. Patients were grouped according to the cumulative dose of peginterferon received, either >80% of the total maximum cumulative peginterferon dose or ≤80% of this dose. The dose of ribavirin was calculated by averaging the mean ribavirin dose (mg) taken by each patient every day during their treatment, dividing the average by the patient’s baseline body weight (kg), and rounding to the nearest 0.5 mg/kg. Missed doses were counted as 0 mg of ribavirin. The W20 VR and SVR rates for all patients taking this particular dose of ribavirin were then calculated. Gastroenterology 2007 132, 103-112DOI: (10.1053/j.gastro.2006.11.011) Copyright © 2007 AGA Institute Terms and Conditions